William Blair Starts Chiasma (CHMA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Barclays Starts Chiasma (CHMA) at Overweight
August 10, 2015 7:28 AM EDTBarclays initiated coverage on Chiasma (NASDAQ: CHMA) with an Overweight rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Chiasma click here. For more ratings news on Chiasma click here.
Shares of Chiasma closed at $23.83 yesterday.
... MoreCowen Starts Chiasma (CHMA) at Outperform
August 10, 2015 6:25 AM EDTCowen initiates coverage on Chiasma (NASDAQ: CHMA) with a Outperform rating and a price target of $43.00.
Analyst Ritu Baral commented, "We think Chiasma's TPE-Octreotide will become a key acromegaly treatment in the US/EU. We expect FDA to approve TPE-Octreotide in mid 2016,... More
